Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I mass balance and biotransformation study of oral 14C-MDV3100 in healthy men
NL-OMON35823Phase 1Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Primary endpoints: Radiokinetics, Pharmacokinetics and 3 more. Started Apr 2011; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON35823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35823.